← Guangdong Taienkang Pharmaceutical overview

Guangdong Taienkang Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangdong Taienkang Pharmaceutical Co. Ltd (301263.CS)

Q3 20263 Aug – 9 Oct 2026

▲3▼1

Profit Collapse Offset by Drug Approvals and Pipeline Progress

Interim Profit Plunges 90% First-half 2026 net profit fell 89.97% to 3.72 million yuan on revenue of 320 million yuan, down 7.72%. This weak result is the main drag on the stock, showing core earnings are under heavy pressure despite better cash flow.
The profit collapse is the single biggest negative force on the stock this period.
New Drug Approvals Expand Product Line The subsidiary won registration certificates for labetalol hydrochloride tablets (hypertension) and diquafosol sodium eye drops (dry eye). These add approved products to sell, supporting future revenue, though both face competition and are not immediate profit drivers.
Two regulatory approvals are concrete new products that can generate future sales.
Procurement Win and Pipeline Milestones Baricitinib tablets were selected in the 12th national centralized procurement, guaranteeing hospital sales volume. Separately, cisplatin polymeric micelle won clinical trial approval and CKBA cream showed strong Phase IIa rosacea results, advancing the innovative pipeline.
These are the main growth catalysts: guaranteed procurement volume plus clinical progress.
Buybacks and Cell Therapy Deal Support Sentiment The company repurchased 2.43 million shares for 48.44 million yuan, signaling confidence. It also secured exclusive China promotion rights for an ocular surface cell therapy product, though that deal is a framework arrangement with no near-term earnings impact.
Buybacks and a strategic partnership are supporting forces, but both are modest in effect.

September 20263 Aug – 9 Oct 2026

▲3▼1

Profit Collapse Offset by Drug Approvals and Pipeline Progress

Interim Profit Plunges 90% First-half 2026 net profit fell 89.97% to 3.72 million yuan on revenue of 320 million yuan, down 7.72%. This weak result is the main drag on the stock, showing core earnings are under heavy pressure despite better cash flow.
The profit collapse is the single biggest negative force on the stock this period.
New Drug Approvals Expand Product Line The subsidiary won registration certificates for labetalol hydrochloride tablets (hypertension) and diquafosol sodium eye drops (dry eye). These add approved products to sell, supporting future revenue, though both face competition and are not immediate profit drivers.
Two regulatory approvals are concrete new products that can generate future sales.
Procurement Win and Pipeline Milestones Baricitinib tablets were selected in the 12th national centralized procurement, guaranteeing hospital sales volume. Separately, cisplatin polymeric micelle won clinical trial approval and CKBA cream showed strong Phase IIa rosacea results, advancing the innovative pipeline.
These are the main growth catalysts: guaranteed procurement volume plus clinical progress.
Buybacks and Cell Therapy Deal Support Sentiment The company repurchased 2.43 million shares for 48.44 million yuan, signaling confidence. It also secured exclusive China promotion rights for an ocular surface cell therapy product, though that deal is a framework arrangement with no near-term earnings impact.
Buybacks and a strategic partnership are supporting forces, but both are modest in effect.

Latest3 Aug – 9 Oct 2026

▲3▼1

Profit Collapse Offset by Drug Approvals and Pipeline Progress

Interim Profit Plunges 90% First-half 2026 net profit fell 89.97% to 3.72 million yuan on revenue of 320 million yuan, down 7.72%. This weak result is the main drag on the stock, showing core earnings are under heavy pressure despite better cash flow.
The profit collapse is the single biggest negative force on the stock this period.
New Drug Approvals Expand Product Line The subsidiary won registration certificates for labetalol hydrochloride tablets (hypertension) and diquafosol sodium eye drops (dry eye). These add approved products to sell, supporting future revenue, though both face competition and are not immediate profit drivers.
Two regulatory approvals are concrete new products that can generate future sales.
Procurement Win and Pipeline Milestones Baricitinib tablets were selected in the 12th national centralized procurement, guaranteeing hospital sales volume. Separately, cisplatin polymeric micelle won clinical trial approval and CKBA cream showed strong Phase IIa rosacea results, advancing the innovative pipeline.
These are the main growth catalysts: guaranteed procurement volume plus clinical progress.
Buybacks and Cell Therapy Deal Support Sentiment The company repurchased 2.43 million shares for 48.44 million yuan, signaling confidence. It also secured exclusive China promotion rights for an ocular surface cell therapy product, though that deal is a framework arrangement with no near-term earnings impact.
Buybacks and a strategic partnership are supporting forces, but both are modest in effect.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.